64 results on '"Bourdin, Arnaud"'
Search Results
2. Sacubitril/valsartan has an underestimated impact on the right ventricle in patients with sleep-disordered breathing, especially central sleep apnoea syndrome
3. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma
4. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma
5. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics
6. Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial
7. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
8. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
9. Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective
10. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study
11. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
12. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version
13. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
14. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
15. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline
16. Patients' and physicians’ perspectives on the burden and management of asthma: Results from the APPaRENT 2 study
17. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
18. Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021
19. Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
20. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
21. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
22. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial
23. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
24. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease
25. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years
26. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process
27. Differentiating between active and latent tuberculosis with chest computed tomography
28. Identifier et prendre en charge l’asthme difficile
29. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC
30. Potential Severe Asthma Hidden in UK Primary Care
31. “Real-life” management of patients with severe asthma in the biologics era: Can we do better?
32. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
33. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
34. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study
35. International Severe Asthma Registry: Mission Statement
36. The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database
37. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
38. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
39. RV function improvement following nitric oxide inhalation demonstrated by gated blood pool SPECT in a patient with primary pulmonary hypertension
40. Longitudinal patterns of intermittent oral corticosteroid therapy for asthma in the United Kingdom
41. The HHIP gene: from a candidate to an established participant in COPD susceptibility
42. Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension
43. Persistent severe hypereosinophilic asthma is not associated with airway remodeling
44. Prognostic value of cluster analysis of severe asthma phenotypes
45. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry
46. CLINICAL OUTCOMES IN PATIENTS WITH SEVERE ASTHMA WHO HAD OR HAD NOT INITIATED BIOLOGIC THERAPY: RESULTS FROM THE CLEAR STUDY
47. CLINICAL OUTCOMES AND EMERGENCY HEALTH CARE UTILIZATION IN PATIENTS WITH SEVERE ASTHMA WHO CONTINUED, SWITCHED, OR STOPPED BIOLOGIC THERAPY: RESULTS FROM THE CLEAR STUDY
48. Generation of a healthy heavy smoker patient-derived induced pluripotent stem cell line UHOMi007-A from peripheral blood mononuclear cells
49. Non-optimal methodology questions indirect treatment comparison of dupilumab vs. other biologics in severe asthma
50. PD-L1 inhibitor-induced worsening of eosinophilic obstructive lung disease successfully rescued with anti-interleukin 5 receptor (IL-5R) therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.